文献速递胰腺与胆道疾病

胰酶治疗降低急性复发性或慢性胰腺炎患儿胰腺炎发作频率:来自INSPPIRE的报告

Pancreatic Enzyme Use Reduces Pancreatitis Frequency in Children With Acute Recurrent or Chronic Pancreatitis: A Report From INSPPIRE.
PubMed 文献 · Am J Gastroenterol · 2024-03-22

该回顾性队列研究纳入INSPPIRE-2队列中胰腺功能充足的急性复发性胰腺炎(ARP)或慢性胰腺炎(CP)患儿,评估胰酶治疗(PERT)对临床结局的影响。356例参与者中60例(17%)接受PERT,其中42%在平均2.1年随访中未再发生急性胰腺炎(AP)发作;启动PERT后AP年平均发病率从3.14降至0.71(P<0.001)。作者认为结果支持开展临床试验评估PERT疗效。

要点

  • 在胰腺功能充足的ARP或CP患儿中,17%(60/356)接受了胰酶治疗(PERT)。
  • 接受PERT者中42%在平均2.1年随访内未再发生AP发作。
  • 启动PERT后AP年平均发病率从3.14降至0.71(P<0.001)。

核心结论

  • 回顾性分析显示,在胰腺功能充足的ARP或CP患儿中,使用PERT与AP发病率降低相关。
  • 作者认为这些结果支持需要开展临床试验来评估PERT改善ARP或CP患儿临床结局的疗效。

研究设计与样本

  • 回顾性队列研究,纳入INSPPIRE-2队列中胰腺功能充足的ARP或CP患儿。
  • 比较接受与未接受PERT者的临床结局,以及PERT前后AP发作频率。
  • 采用逻辑回归研究启动PERT后AP发作的发生与应答预测因素之间的关联。

主要发现

  • 356例胰腺功能充足的参与者中,270例(76%)为ARP,60例(17%)接受PERT。
  • 接受PERT者中,42%在平均2.1年随访期间未发生后续AP发作。
  • 携带SPINK1突变者(P=0.005)及ARP患者(与CP相比,P=0.008)在启动PERT后发生AP发作的可能性更低。
  • 启动PERT后,AP年平均发病率从3.14降至0.71(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Among children who suffer from acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP), acute pancreatitis (AP) episodes are painful, often require hospitalization, and contribute to disease complications and progression. Despite this recognition, there are currently no interventions to prevent AP episodes. In this retrospective cohort study, we assessed the impact of pancreatic enzyme therapy (PERT) use on clinical outcomes among children with pancreatic-sufficient ARP or CP. METHODS: Children with pancreatic-sufficient ARP or CP in the INSPPIRE-2 cohort were included. Clinical outcomes were compared for those receiving vs not receiving PERT, as well as frequency of AP before and after PERT. Logistic regression was used to study the association between development of AP episodes after starting PERT and response predictors. RESULTS: Among 356 pancreatic-sufficient participants, 270 (76%) had ARP, and 60 (17%) received PERT. Among those on PERT, 42% did not have a subsequent AP episode, during a mean 2.1 years of follow-up. Children with a SPINK1 mutation ( P = 0.005) and those with ARP (compared with CP, P = 0.008) were less likely to have an AP episode after starting PERT. After initiation of PERT, the mean AP annual incidence rate decreased from 3.14 down to 0.71 ( P < 0.001). DISCUSSION: In a retrospective analysis, use of PERT was associated with a reduction in the incidence rate of AP among children with pancreatic-sufficient ARP or CP. These results support the need for a clinical trial to evaluate the efficacy of PERT to improve clinical outcomes among children with ARP or CP.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Freeman AJ, Ng K, Wang F, et al. Pancreatic Enzyme Use Reduces Pancreatitis Frequency in Children With Acute Recurrent or Chronic Pancreatitis: A Report From INSPPIRE. Am J Gastroenterol. 2024. PMID: 38517077. doi:10.14309/ajg.0000000000002772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。